GLTO Projected Dividend Yield
Galecto Inc ( NASDAQ : GLTO )Galecto is a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Co.'s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. Co.'s primary product candidate, GB0139, is an inhaled inhibitor of galectin-3. Co. is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. 20 YEAR PERFORMANCE RESULTS |
GLTO Dividend History Detail GLTO Dividend News GLTO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |